Long on Meds Blog
Can Low-Dose Naltrexone Help Protect My Brain?
Low-dose naltrexone has not been proven to prevent cognitive decline or dementia, but it has several biologically plausible effects on neuroinflammation, encouraging animal data, preliminary human CNS signals, and a generally favorable low-dose safety profile. For me, that combination makes it worth considering as a potential preventive strategy.
Why might low-dose naltrexone affect the brain?
Naltrexone is best known as an opioid receptor antagonist. At much lower doses, typically 1 to 4.5 mg daily, it appears to have additional effects on immune signaling.
One proposed mechanism involves microglia, the immune cells of the brain. LDN appears to modulate Toll-like receptor 4, or TLR4, signaling on microglia, potentially reducing downstream inflammatory signals including IL-1 and TNF-alpha. Another proposed mechanism involves temporary opioid-receptor blockade followed by changes in endogenous endorphin signaling.
In plain language, the possibility that interests me is that LDN may help turn down unnecessary inflammatory activity within the nervous system.
Is there evidence that LDN can protect the nervous system?
There is encouraging animal evidence, although it cannot establish benefit in humans.
In a mouse model involving traumatic brain injury and seizures, naltrexone reduced microglial activation and neuronal degeneration. Another mouse study involving diabetic ischemic stroke found that low-dose naltrexone increased beta-endorphin and opioid growth factor and was associated with improved neuronal recovery.
These findings provide biological support for neuroprotection, but they are not evidence that LDN prevents Alzheimer's disease or dementia in people.
Is there any evidence in people?
There are preliminary signals, but the evidence remains limited.
A small randomized trial in multiple sclerosis reported improvement in perceived cognitive function and mental-health quality of life with 4.5 mg daily. Observational studies of long COVID have also reported improvement in brain fog, memory, and concentration in some patients taking LDN. Other MS studies, however, have not demonstrated convincing improvements in objective disease measures.
So I consider the human evidence interesting rather than definitive.
Why did I decide to take LDN?
I had considerable experience with naltrexone during my career in pain management. Where low-dose naltrexone particularly caught my attention was in younger women with longstanding fibromyalgia.
It was not a cure, and pain relief was inconsistent. But I repeatedly saw patients who felt that their mood improved and they functioned better. I did not see LDN reverse cognitive decline in my older patients, and I would not make that claim.
Those clinical observations, combined with the emerging research on neuroinflammation, eventually made me interested in taking 4.5 mg daily myself as a potential strategy for brain protection.
How safe is low-dose naltrexone?
LDN has generally been well tolerated in published studies. The most commonly reported adverse effects include vivid dreams or sleep disturbance, nausea, headache, dizziness, and mild gastrointestinal symptoms. Serious toxicity signals at low doses have been uncommon, although rigorous safety studies specifically in high-risk older adults remain limited.
Opioids require special attention. Naltrexone blocks opioid receptors and can interfere with opioid treatment or precipitate withdrawal. Anyone taking opioid medication should discuss LDN specifically with the prescribing physician before considering it.
Why might I consider LDN rather than a supplement?
Many people take supplements hoping to protect their brains even though evidence that those supplements prevent cognitive decline is limited. I prefer to ask a different question: what intervention has a plausible mechanism relevant to the biological process I am trying to influence, and what is its risk at the dose I would actually use?
LDN is a defined pharmaceutical with known pharmacology and a specific proposed effect on neuroinflammatory signaling. It has not been proven to protect the aging human brain, but its mechanistic evidence, animal findings, preliminary human CNS signals, and generally favorable low-dose tolerability make the potential benefit-to-risk ratio compelling enough for me to take it.
That is the third level of Long on Meds: not assuming that an unproven medication works, but considering whether a carefully selected low-dose medication offers enough potential preventive benefit, at sufficiently low risk, to justify discussing it with your physician.
Learn more about inflammaging and inflammatory pathways, or use Check a Medication to examine naltrexone and other medications.